Trial · NCT02235909
Participant flow99
How many started, completed or left each group, period by period.
1 to 20 of 99
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Double-Blind Phase | STARTED | Active Comparator: Double Blind Phase: Losartan | 53 | |
| Double-Blind Phase | STARTED | Experimental: Double-blind: Azilsartan Medoxomil - Low Dose | 52 | |
| Double-Blind Phase | STARTED | Experimental: Double-blind: Azilsartan Medoxomil - Medium Dose | 56 | |
| Double-Blind Phase | STARTED | Experimental: Double-blind: Azilsartan Medoxomil - High Dose | 54 | |
| Double-Blind Phase | STARTED | Placebo Comparator: Withdrawal Phase: PLACEBO | 0 | |
| Double-Blind Phase | STARTED | Active Comparator: Withdrawal Phase: Losartan 50 mg | 0 | |
| Double-Blind Phase | STARTED | Active Comparator: WITHDRAWAL Phase: Azilsartan Medoxomil LOW-dose | 0 | |
| Double-Blind Phase | STARTED | Experimental: WITHDRAWAL Azilsartan Medoxomil - Medium Dose | 0 | |
| Double-Blind Phase | STARTED | Experimental: WITHDRAWAL Azilsartan Medoxomil - High Dose | 0 | |
| Double-Blind Phase | STARTED | Azilsartan Medoxomil Alone | 0 | |
| Double-Blind Phase | STARTED | AZM Plus | 0 | |
| Double-Blind Phase | COMPLETED | Active Comparator: Double Blind Phase: Losartan | 47 | |
| Double-Blind Phase | COMPLETED | Experimental: Double-blind: Azilsartan Medoxomil - Low Dose | 52 | |
| Double-Blind Phase | COMPLETED | Experimental: Double-blind: Azilsartan Medoxomil - Medium Dose | 53 | |
| Double-Blind Phase | COMPLETED | Experimental: Double-blind: Azilsartan Medoxomil - High Dose | 51 | |
| Double-Blind Phase | COMPLETED | Placebo Comparator: Withdrawal Phase: PLACEBO | 0 | |
| Double-Blind Phase | COMPLETED | Active Comparator: Withdrawal Phase: Losartan 50 mg | 0 | |
| Double-Blind Phase | COMPLETED | Active Comparator: WITHDRAWAL Phase: Azilsartan Medoxomil LOW-dose | 0 | |
| Double-Blind Phase | COMPLETED | Experimental: WITHDRAWAL Azilsartan Medoxomil - Medium Dose | 0 | |
| Double-Blind Phase | COMPLETED | Experimental: WITHDRAWAL Azilsartan Medoxomil - High Dose | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02235909/flow